Celgene profit beats as psoriasis drug sales surge

Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

CONCLUSION: The ULISSE study indicated that enthesitis is a common feature in patients with PsA, those with psoriasis, and in those with FMS if only clinical examination is used. US entheseal assessment showed findings more consistent with the 3 disorders. PMID: 30877205 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
AbstractIL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently  switched to another drug of this class. After 12 weeks of treatment, patients’ PASIs were evaluated. Treatme...
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
ConclusionCertolizumab is efficacious in both psoriasis and PsA, including in patients who are biologic failures, and could be considered as an alternative treatment modality.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
Herpes zoster (HZ) incidence is linked to immunosuppression. Patients with psoriasis (PsO) and/or psoriatic arthritis (PsA) on systemic therapy may be at increased risk for HZ.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Condition:   Psoriasis Vulgaris Intervention:   Drug: oral vitamin D Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Psoriasis Interventions:   Drug: Risankizumab;   Device: Autoinjector Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Psoriasis Interventions:   Drug: Risankizumab;   Drug: Placebo Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Psoriasis Vulgaris Intervention:   Drug: oral vitamin D Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Psoriasis Interventions:   Drug: Risankizumab;   Device: Autoinjector Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Psoriasis Interventions:   Drug: Risankizumab;   Drug: Placebo Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Health | Profits and Losses | Psoriasis